GW501516, a PPARδ Agonist, Ameliorates Tubulointerstitial Inflammation in Proteinuric Kidney Disease via Inhibition of TAK1-NFκB Pathway in Mice

Xu Yang1,2, Shinji Kume1, Yuki Tanaka1, Keiji Isshiki1, Shin-ichi Araki1, Masami Chin-Kanasaki1, Toshiro Sugimoto1, Daisuke Koya3, Masakazu Haneda4, Takeshi Sugaya5, Detian Li2, Ping Han2, Yoshihiko Nishio1, Atsunori Kashiwagi1, Hiroshi Maegawa1, Takashi Uzu1*  

1 Department of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan, 2 Department of Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China, 3 Division of Endocrinology and Metabolism, Kanazawa Medical University, Kahoku-Gun, Ishikawa, Japan, 4 Department of Medicine, Asahikawa Medical College, Asahikawa, Hokkaido, Japan, 5 Nephrology and Hypertension, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan

Abstract

Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor family of ligand-inducible transcription factors, which have three different isoforms: PPARα, δ and γ. It has been demonstrated that PPARα and γ agonists have renoprotective effects in proteinuric kidney diseases; however, the role of PPAR δ agonists in kidney diseases remains unclear. Thus, we examined the renoprotective effect of GW501516, a PPARδ agonist, in a protein-overload mouse nephropathy model and identified its molecular mechanism. Mice fed with a control diet or GW501516-containing diet were intraperitoneally injected with free fatty acid (FFA)-bound albumin or PBS(-). In the control group, protein overload caused tubular damages, macrophage infiltration and increased mRNA expression of MCP-1 and TNFα. These effects were prevented by GW501516 treatment. In proteinuric kidney diseases, excess exposure of proximal tubular cells to albumin, FFA bound to albumin or cytokines such as TNFα is detrimental. In vitro studies using cultured proximal tubular cells showed that GW501516 attenuated both TNFα- and FFA (palmitate)-induced, but not albumin-induced, MCP-1 expression via direct inhibition of the TGF-β-activated kinase 1 (TAK1)-NFκB pathway, a common downstream signaling pathway to TNFα receptor and toll-like receptor-4. In conclusion, we demonstrate that GW501516 has an anti-inflammatory effect in renal tubular cells and may serve as a therapeutic candidate to attenuate tubulointerstitial lesions in proteinuric kidney diseases.

Introduction

Proteinuria is not only a clinical indicator of chronic kidney disease (CKD), but also a detrimental factor in progressive CKD [1,2,3]. In proteinuric kidney diseases, excessive albumin and several macromolecules bound to albumin, including free fatty acid (FFA), are filtered from glomeruli and reabsorbed into proximal tubular cells. This causes an inflammatory vicious cycle via secretion of pro-inflammatory cytokines, such as monocyte chemoattractant protein-1 (MCP-1), and subsequent infiltration of inflammatory cells, which secrete tumor necrotic factor-α (TNFα) [1,2,3,4,5]. Continuous inflammation triggers tubular cell damage, fibrosis and eventually progression to the final stage of kidney disease [5,6]. Thus, suppression of inflammation caused by all these factors should serve as an important means to protect proximal tubular cells and maintain renal function in proteinuric kidney diseases.

Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor family of ligand-inducible transcription factors, composed of three different isoforms: PPARα, PPARδ and PPARγ [7,8]. Acting as transcription factors, PPARs regulate various metabolic processes involving lipid metabolism, glucose homeostasis, cell differentiation and inflammation [7,8,9,10,11]. Recent reports demonstrated that PPARα and γ agonists show renoprotective effects in a PPAR-dependent and independent manner [12,13,14,15,16,17]; however, the physiological role and therapeutic potential of PPARδ in the kidney remain unclear. Several reports have shown that PPARδ agonists are potentially anti-inflammatory agents in some cell types and animal models [18,19,20,21]. In summary, PPARδ agonists may show anti-inflammatory effects in renal proximal tubular cells and could be promising new therapeutic candidates for proteinuric kidney diseases.

To certify this hypothesis, we investigated whether GW501516, a highly selective PPARδ agonist [22], could attenuate tubulointerstitial lesions in a protein-overload mouse model [an established mouse model for studying interstitial lesions in proteinuric kidney diseases [4,23]], and whether it could inhibit albumin-, saturated FFA (palmitate)- and TNFα-induced inflammation in cultured mouse proximal tubular cells. Our results showed that GW501516...
exerted an anti-inflammatory effect in proximal tubular cells in both in vivo and in vitro studies, and it may be a promising new candidate for slowing down the progression of proteinuric kidney diseases.

Results

GW501516 attenuates interstitial inflammation and proximal tubular cell damage in a protein-overload mouse nephropathy model

To determine whether PPARδ agonists exert anti-inflammatory effects in vivo, we examined the effect of GW501516 on a protein-overload mouse model. First, we confirmed that bovine serum albumin (BSA) injection in mice increased urinary protein excretion, and that treatment with GW501516 did not affect basal and BSA-induced urinary protein excretion [(PBS(−) group: 3.26±0.66, PBS(−) + GW501516 group: 3.21±0.70, BSA group: 6.36±1.26, BSA + GW501516 group: 6.60±1.93 mg/day; data are shown as means ± SEM)]. In mice fed with the control diet, intraperitoneal protein overload induced significant and severe tubular injury, characterized by diffused tubular cell vacuolation, tubular cell flattening, tubular lumen dilation and cast formation (Figure 1A and B). In the mice fed with the GW501516-containing diet, these tubulointerstitial damages were significantly attenuated (Figure 1A and B). The PBS(−) injection resulted in no apparent changes in proximal tubular cells of either control or GW501516-treated groups (Figure 1A and B).

Protein overload induced the prominent infiltration of F4/80-positive macrophages into the renal interstitial area, which was markedly attenuated by GW501516 treatment (Figure 2A). Infiltration of F4/80-positive macrophages into glomeruli was not observed in the kidney of any group of mice (Figure 2A). The changes in F4/80 expression were confirmed by mRNA levels, determined by real-time PCR (Figure 2B). Furthermore, protein overload significantly increased mRNA expression levels of inflammatory cytokines such as MCP-1, TNFα and IL-6. These increases were significantly attenuated by GW501516 treatment (Figure 2C, D and E). Protein overload and GW501516 treatment did not affect PPARδ expression levels in mice (data not shown). These results suggest that GW501516 shows an anti-inflammatory effect and protection of proximal tubular cells in the proteinuric kidney disease mouse model.

GW501516 exerts anti-inflammatory effects in mouse cultured proximal tubular (mProx) cells

Because proximal tubular cells are the direct victims of overflowed protein [1,2,3], we examined the anti-inflammatory effect of GW501516 on cultured mouse proximal tubular cells, treated with pro-inflammatory molecules associated with proteinuria-induced inflammation, such as FFA-free albumin [24,25], albumin-bound saturated FFA (palmitate) [26] and TNFα. GW501516 failed to inhibit FFA-free albumin-induced MCP-1 expression (Figure 3A). However, GW501516 inhibited palmitate- and TNFα-induced increases in MCP-1 mRNA expression in a dose-dependent manner (Figure 3B and C). These stimuli and treatment did not affect PPARδ expression levels (data not shown). These results suggest that the GW501516-mediated suppression of MCP-1 expression is specific to palmitate and TNFα in cultured mProx cells.
PPARδ is not required for GW501516-mediated anti-inflammatory effects in cultured proximal tubular (mProx) cells

The molecular mechanism of PPAR agonist-mediated anti-inflammatory effects is cell-dependent [11,27]. Also, some PPAR agonists have been shown to have an anti-inflammatory effect via direct inhibition of an intracellular signaling pathway, but not via ligand-activation of PPARs and subsequent upregulation of their target genes [11,27]. Thus, we investigated whether PPARδ itself is required for the anti-inflammatory effect of GW501516 in cultured mProx cells, using siRNA-mediated PPARδ knockdown and retrovirus-mediated PPARδ overexpression. We confirmed the decreased PPARδ protein expression in siRNA-mediated PPARδ-knockdown mProx cells (Figure 4A). Furthermore, the mRNA level of PPARδ target genes was decreased in these cells (Figure 4B). GW501516 significantly attenuated both palmitate- and TNFα-induced MCP-1 expression levels in mProx cells transfected with control siRNA (Figure 4C and D). This response was not affected by siRNA-mediated PPARδ knockdown (Figure 4C and D). Moreover, we generated retrovirus-mediated PPARδ-overexpressing mProx cells and confirmed the functional overexpression of PPARδ (Figure 5A and B). The GW501516 inhibitory effect on both palmitate- and TNFα-induced MCP-1 expression was not enhanced in retrovirus-mediated PPARδ-overexpressing mProx cells (Figure 5C and D). Thus, neither knockdown nor overexpression of PPARδ changed the anti-inflammatory effect of GW501516. These results suggest that PPARδ itself is not essential for the anti-inflammatory effect of GW501516.

GW501516 exerts its anti-inflammatory effect by inhibition of the TAK1-NFκB pathway

We continued to elucidate the identity of the signaling molecules involved in the anti-inflammatory effect of GW501516, specifically focusing on signaling molecules associated with the NFκB pathway, which is a main inflammation regulatory pathway. In cultured mProx cells incubated with palmitate, phosphorylation of IκB and subsequent nuclear translocation of
Figure 3. GW501516 inhibits palmitate- and TNFα-induced MCP-1 expression in mouse proximal tubular (mProx) cells. mRNA expression of MCP-1 determined by real-time PCR in cultured mProx cells stimulated by 30% BSA (A), 150 µM palmitate (B) or 10 nM of TNFα (C) for 12 hours, with or without a 3-hour pretreatment of different concentrations of GW501516 (0, 2.5, 5 µM of GW501516 dissolved in 0.05% DMSO). Results are expressed as fold change relative to control mRNA levels. Data are shown as means ± SEM of at least four independent experiments. MCP-1: monocyte chemoattractant protein-1; BSA: bovine serum albumin; TNFα: tumor necrotic factor α. doi:10.1371/journal.pone.0025271.g003

Figure 4. Knockdown of PPARα gene expression does not affect GW501516-mediated inhibition of MCP-1 expression in mouse proximal tubular (mProx) cells treated with palmitate or TNFα. (A) Representative immunoblot showing protein expression of PPARα in siRNA-mediated PPARα-knockdown and control cells. (B) mRNA expression of PPARα-target genes (PDK4 and ADRP) in PPARα-knockdown and control cells treated with or without GW501516. Results are expressed as fold change relative to the mRNA from the control group. PDK4: Pyruvate dehydrogenase kinase 4; ADRP: Adipocyte differentiation-related protein. The effect of PPARα knockdown on GW501516-mediated inhibition of palmitate- (C) and TNFα- (D) induced MCP-1 expression. Results are expressed as fold change relative to the mRNA from the control group. Data are shown as means ± SEM of three independent experiments. MCP-1: monocyte chemoattractant protein-1; TNFα: tumor necrotic factor α. doi:10.1371/journal.pone.0025271.g004

Figure 5. Overexpression of PPARα does not affect GW501516-mediated attenuation of MCP-1 expression in mouse proximal tubular (mProx) cells treated with palmitate or TNFα. (A) Representative immunoblot showing protein expression of PPARα in retrovirus-mediated PPARα-overexpressing cells and control cells. (B) mRNA expression of PPARα-target genes (PDK4 and ADRP) in PPARα-overexpressing and control cells treated with or without GW501516. Results are expressed as fold change relative to the mRNA from the control group. PDK4: Pyruvate dehydrogenase kinase 4; ADRP: Adipocyte differentiation-related protein. The effect of PPARα overexpression on GW501516-mediated inhibition of palmitate- (C) and TNFα- (D) induced MCP-1 expression. Results are expressed as fold change relative to the mRNA from the control group. Data are shown as means ± SEM of four independent experiments. MCP-1: monocyte chemoattractant protein-1; TNFα: tumor necrotic factor α. doi:10.1371/journal.pone.0025271.g005
the p65 component of NFκB were observed after 1 hour of stimulation (Figure 6A). Palmitate-induced phosphorylation of IκB and nuclear translocation of p65 were attenuated by pretreatment with GW501516 (Figure 6B). Furthermore, we found that GW501516 inhibited palmitate-induced DNA binding of p65 to the MCP-1 promoter, as determined by chromatin immunoprecipitation (ChIP) analysis (Figure 6C). Next, we checked the profiles of upstream and regulatory molecules associated with receptor-mediated NFκB activation, such as mitogen activated protein kinases (MAPKs; ERK, p38 and JNK) [28,29] and TGF-β activated kinase 1 (TAK1) [30,31]. The phosphorylation levels of the MAPKs and TAK1 were increased after 1 hour of palmitate stimulation (Figure 6D). GW501516 inhibited the palmitate-induced phosphorylation of TAK1 (Figure 6E and F), but not of the MAPKs (Figure 6E).

Furthermore, we observed similar results with cultured mProx cells incubated with TNFα. TNFα increased IκB phosphorylation and subsequent nuclear translocation of p65 after 5 minutes of stimulation (Figure 7A and 7B). These changes and DNA binding of p65 to the MCP-1 promoter were significantly attenuated by pretreatment with GW501516 (Figure 7C and D, respectively).

Finally, TAK1 phosphorylation was increased after 5 hours of TNFα stimulation (Figure 7E and F), which was suppressed by pretreatment with GW501516 (Figure 7E and F).

GW501516 inhibited palmitate- and TNFα-induced phosphorylation of TAK1 and IκB, and subsequent nuclear translocation of p65 even in mProx cells transfected with siRNA against PPARδ (Figure 8A and B), suggesting that GW501516 inhibited the TAK1-IκB pathway directly.

To investigate whether PPARδ agonist-mediated inhibition of TAK1 activation was specific to GW501516, we examined the anti-inflammatory effect and mechanism of another PPARδ agonist, GW0742, in mProx cells. Similarly to GW501516, GW0742 inhibited both palmitate- and TNFα-induced MCP-1 expression (Figure 9A and B) and suppressed TAK1 phosphorylation (Figure 9C, D, E and F). These results suggest that PPARδ agonist-mediated inhibition of TAK1 activation is not specific to GW501516.

Discussion

The present study shows that GW501516 attenuated tubulointerstitial lesions in a protein-overload nephropathy mouse model and that its renoprotective effect was achieved by its anti-inflammatory action in the kidney. These results highlight the possibility that GW501516 may be a novel therapeutic candidate for the improvement of renal prognosis in patients with proteinuric kidney diseases.

Growing evidence has demonstrated that PPARδ agonists have therapeutic potential against various disease models [18,19,20,21,22,23,32,33,34]. Recent reports have shown that PPARδ agonists attenuated obesity-related diseases such as insulin resistance, diabetes and cardiovascular diseases, and regulated inflammatory cell function, which potentiated a systemic inflammatory response [18,19,20,21,22,23,32,33,34]. Furthermore, Letavernier et al. showed the renoprotective effect of a PPARδ agonist in an ischemic reperfusion-mediated kidney injury [35]. In addition to these findings, we present evidence that PPARδ agonists have yet more therapeutic potential against proteinuric kidney diseases.

The protein-overload model is a well-established model for studying the renal tubulointerstitial lesions caused by proteinuria [4,23]. In this model, upregulation of MCP-1 was demonstrated...
and the anti-MCP-1 gene therapy attenuated interstitial lesions [36], which verified that attenuation of inflammation through inhibition of MCP-1 should serve as a therapeutic target in proteinuric kidney diseases. In our study, we confirmed that protein overload induced MCP-1 expression and subsequent renal inflammation, and these inflammation-associated renal damages were attenuated by treatment with GW501516. To our knowledge, this is the first report showing that a pharmacological agent can improve tubulointerstitial lesions in this model.

Our in vitro study has identified the detailed molecular mechanism underlying the anti-inflammatory effect of GW501516 in the kidney. In proteinuric kidney diseases, albumin, FFAs bound to albumin and inflammatory cytokines coordinately mediate interstitial inflammation. In this study, we confirmed that all of these factors induced overexpression of MCP-1 in cultured proximal tubular cells via NFkB activation. Interestingly, GW501516 attenuated MCP-1 expression induced by palmitate and TNFalpha, but not albumin. These results suggest that the anti-inflammatory effect of GW501516 is not universal in NFkB-associated inflammatory processes; hence we focused on the upstream signaling to NFkB. NFkB activation is regulated by a variety of molecular pathways such as MAPKs and TAK1.

Figure 7. GW501516 inhibits TNFalpha-induced NFkB activation via inhibition of TAK1 in mouse proximal tubular (mProx) cells. Immunoblot analysis showing TNFalpha-induced phosphorylation of IkB and TAK1 (A) and nuclear translocation of the p65 subunit (B) in a time course experiment. (C) Immunoblot analysis showing the effect of GW501516 on TNFalpha-induced phosphorylation of IkB and nuclear translocation of p65. The pretreatment time with GW501516 was 3 hours and the stimulation time with TNFalpha was 5 minutes for phosphorylation of IkB and 10 minutes for nuclear translocation of p65. Images are representative results from three independent experiments. (D) Effect of GW501516 on DNA binding of p65 to the MCP-1 promoter determined by chromatin immunoprecipitation (ChIP) analysis in TNFalpha-treated mProx cells. (E) Immunoblot analysis showing the effect of GW501516 on TAK1 phosphorylation. Pre-incubation time with GW501516 was 10 hours and stimulation time with TNFalpha was 3 hours. (F) Quantitative result of the ratio of band density of P-TAK1 and T-TAK1. Images are representative figures from three independent experiments. TAK1: TGF-beta activated kinase 1; TNFalpha: tumor necrotic factor alpha.
doi:10.1371/journal.pone.0025271.g007

Figure 8. Knockdown of PPARdelta gene expression does not affect the GW501516-mediated inhibitory effect on the TAK1-NFkB pathway in mouse proximal tubular (mProx) cells treated with palmitate or TNFalpha. Immunoblot analysis showing the effect of GW501516 on palmitate- (A) and TNFalpha- (B) induced phosphorylation of IkB and TAK1 in total cell lysate and nuclear translocation of the p65 subunit in siRNA-mediated PPARdelta-knockdown and control cells. Images are representative figures from three independent experiments. TAK1: TGF-beta activated kinase 1; TNFalpha: tumor necrotic factor alpha.
doi:10.1371/journal.pone.0025271.g008
 experiments.

TNFα activity is not the target of the anti-inflammatory effect of GW501516 (Figure 10). To our knowledge, few reports have shown the interaction between PPAR agonists and TAK1. Our current findings may enrich the knowledge of anti-inflammatory mechanisms of PPAR agonists. Thus, for the first time, we concluded that inhibition of albumin failed to induce phosphorylation of TAK1 (data not shown). Therefore, for the first time, we concluded inhibition of TAK1, but not of MAPKs (including ERK), and the activation of the NFκB-associated inflammatory response in proximal tubular cells. TNFα: tumor necrotic factor α; TNFR: TNF receptor; TLR4: toll-like receptor 4; IKK: IκB kinase; FFA: free fatty acid; MCP-1: monocyte chemoattractant protein-1. Data are shown as means ± SEM of at least three independent experiments.

doi:10.1371/journal.pone.0025271.g009

Figure 9. GW0742 inhibits palmitate- and TNFα-induced MCP-1 expression as well as TAK1 phosphorylation in mouse proximal tubular (mProx) cells. mRNA expression of MCP-1 determined by real-time PCR in cultured mProx cells stimulated by 150 μM palmitate (A) or 10 nM TNFα (B) for 12 hours, with or without a 3-hour pretreatment with GW0742 (5 μM GW0742 dissolved in 0.05% DMSO). Results are expressed as fold change relative to control mRNA levels. (C) Immunoblot analysis showing palmitate-induced phosphorylation of TAK1. (D) Quantitative result of the ratio of band density of P-TAK1 and T-TAK1. (E) Immunoblot analysis showing TNFα-induced phosphorylation of TAK1. (F) Quantitative result of the ratio of band density of P-TAK1 and P-TAK1. MCP-1: monocyte chemoattractant protein-1. TNFα: tumor necrotic factor α; TAK1: TGF-β activated kinase 1. Data are shown as means ± SEM of at least three independent experiments.

doi:10.1371/journal.pone.0025271.g010

Figure 10. Proposed mechanism underlying the GW051516-mediated anti-inflammatory effect in proximal tubular cells in proteinuric kidney disease. Both TNFα and palmitate induce the phosphorylation of TAK1 in a receptor dependent manner. The phosphorylation of TAK1 activates the NFκB pathway via degradation of IκB. The p65 subunit of NFκB translocates into the nucleus, upregulates the transcription of the pro-inflammatory gene, MCP-1, and causes inflammation. GW501516 can inhibit the phosphorylation of TAK1, but not of MAPKs (including ERK), and the activation of the NFκB-associated inflammatory response in proximal tubular cells. TNFα: tumor necrotic factor α; TNFR: TNF receptor; TLR4: toll-like receptor 4; IKK: IκB kinase; FFA: free fatty acid; MCP-1: monocyte chemoattractant protein-1.

doi:10.1371/journal.pone.0025271.g010

[28,29,30]. Our group previously demonstrated that albumin-induced MCP-1 expression was MAPK (ERK)-dependent [25]. Here we show that GW501516 could not attenuate albumin-induced MCP-1 expression, suggesting that inhibition of ERK activity is not the target of the anti-inflammatory effect of GW501516. In contrast, GW501516 inhibited palmitate- and TNFα-induced MCP-1 expression via the inhibition of TAK1 activation, without affecting MAPK activity. Furthermore, albumin failed to induce phosphorylation of TAK1 (data not shown). Thus, for the first time, we concluded that inhibition of TAK1, but not MAPKs, is involved in the mechanism underlying the anti-inflammatory effect of GW501516 (Figure 10). To our knowledge, few reports have shown the interaction between PPARδ agonists and TAK1. Our current findings may enrich the knowledge of anti-inflammatory mechanisms of PPAR δ agonists.

To date, the mechanism underlying the anti-inflammatory effect of PPARδ agonists has been focused on BCL6 protein. The release of BCL6 from PPARδ is known to contribute to any of the anti-inflammatory actions of PPARδ agonists in macrophages, both in vitro [21,37] and in vivo [21]. In other tissues it is not so clear; the inhibitory actions of PPARδ on adhesion molecules expression in endothelial cells have been reported to be both BCL6-dependent [38] and BCL6-independent [39], suggesting that the BCL6 theory is cell-specific and ligand-specific. We showed that suppression of PPARδ gene expression had no effect on MCP-1 expression in mProx cells, indicating that BCL6 is not involved in the anti-inflammatory mechanism of GW501516 in proximal tubular cells.

Also in our study, we demonstrated that PPARδ itself is not essential for the anti-inflammatory effect of GW501516. The knockdown or overexpression of PPARδ could neither impede nor enhance the anti-inflammatory action of GW501516. GW501516 has shown to exert an anti-inflammatory effect in many cell types [18,19,20,21], but whether or not this effect is mediated through the PPARδ receptor has not been clarified. Although we demonstrated that two types of PPARδ agonists, GW501516 and GW0742, did not require PPARδ itself for their anti-inflammatory effects in cultured proximal tubular cells, it remains to be confirmed whether all PPARδ agonists function similarly, to conclude whether this mechanism is specific for GW501516 and GW0742 or global for PPARδ agonists. Furthermore, to elucidate whether GW501516 can improve renal inflammation in a PPARδ-independent manner in vivo, further examination of the effect of GW501516 on the progression of tubulointerstitial lesions induced by protein overload in PPARδ knockout mice is required.
In conclusion, we demonstrated that GW501516, a PPARδ agonist, showed a renoprotective effect by exerting an anti-inflammatory effect in proximal tubular cells, both in vivo and in vitro. Thus, it may be a promising candidate for slowing down the progression of chronic kidney diseases.

**Materials and Methods**

**Antibodies and reagents**

Antibodies were purchased from the following sources: TAK1 polyclonal antibody, phospho-TAK1 (T187), IκB-α, phospho-IκBα, p38-MAPK, phospho-p38-MAPK (Thr180/Tyr182), p44/42 MAPK, phospho-p44/p42 MAPK, SAPK/JNK, phospho-SAPK/JNK (T183/Y185), Histone H3 and NFκB p65 were from Cell Signaling Technology (Beverly, MA, USA). Recombinant TNFα, sodium palmitate, albumin from bovine serum and GW0742 were purchased from Sigma (St. Louis, MO, USA). Small interfering RNA against PPARδ was purchased from Applied Biosystems Japan, Ltd. GW501516 was from GlaxoSmithKline (London, UK).

**Animals.**

Animal care and treatment were performed in accordance with the guidelines of the Research Center for Animal Life Science of Shiga University of Medical Science (approval ID: 2010-2-13). Seven-week-old male C57BL/6 mice (CLEA Japan, Tokyo, Japan) were housed at a constant room temperature, 12-h dark/12-h light cycle, and freely fed a standard diet and tap water. Mice were randomly allocated to different groups and received therapeutic diet and treatment. The GW501516-containing rodent diet was made by evenly adding GW501516 to the control diet to a final concentration of 0.04% w/w. In the control diet, 10% of the total calories were from fat (5.5% from soybean oil and 4.5% from lard). All foods were purchased from Research Diets (New Brunswick, NJ, USA).

**Protein-overload mouse nephropathy model**

Animal experiments were performed as described previously, with minor modifications [4,23]. FFA-bound BSA was administered by intraperitoneal injection to induce renal tubulointerstitial damages. Mice were divided into the following four groups: PBS(−), PBS(−) + GW501516, protein-overload and protein-overload + GW501516 (n = 3, 4, 6 and 6, respectively). Mice were fed either a control diet or a GW501516-containing diet. Each group was given its diet for 10 days before starting treatments. Once a day for the following 4 days, the mice of each group were given an intraperitoneal injection of either 10 mg/g body weight FFA-bound BSA diluted in sterile PBS(−) or an equal volume of sterile PBS(−) as a control. On the fifth day, mice were anesthetized with intraperitoneal injection of pentobarbital sodium, then blood was drawn from the right atrium with a heparinized syringe and serum was separated for biochemical assays. Kidneys were removed for mRNA assays, histological examination and immunohistochemical staining, as previously reported [40,41]. Urinary protein concentrations were measured with the Bradford method.

**Histological analyses**

Fixed kidneys embedded in paraffin were sectioned to 3 μm thickness [40,41]. Semi-quantitative histological analysis of the tubular damage was performed using HE-stained sections from each mouse. Tubular damage scores, ranging from 0 to 4, were assessed according to both the severity and range of proximal tubular damages; an average was taken from the final score of 20 randomly selected, non-overlapping cortical areas under ×200 magnification [42]. Immunohistochemical staining was performed with the F4/80-specific monoclonal anti-rat antibody (Serotec, Oxford, UK), as previously described [40].

**Cell culture**

Immortalized murine proximal tubular cells (mProx) were established as described previously [25]. First, we confirmed that the dosage of GW501516 used in the following experiments was not cytotoxic to the cells by using the AlamarBlueTM Assay (Alamar Bioscience, Sacramento, CA, USA; data not shown). Cells were cultured in DMEM containing 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C and 5% CO2 thermostat. Subconfluent cells were starved by incubation in 0.2% FCS DMEM for 9 h, then preincubated with GW501516 [dissolved in 10% dimethyl sulfoxide (DMSO)], at a final concentration of 2.5 and 5 μM, or 0.05% DMSO as control for 3 hours, followed by stimulation with 150 μM palmitate bound to 8.0% BSA for 12 h. We also performed the same experiment under stimulation with 10 nM TNFα and 30% BSA.

**Quantitative real-time PCR**

Total RNAs were isolated from the kidney samples and cultured cells, and cDNAs were synthesized as previously reported [41]. The iQSYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA) was used for real-time PCR (ABI Prism TM7500 Sequence Detection System; PerkinElmer Applied Biosystems, Foster City, CA, USA). The mRNA expression levels were quantified using the standard curve method [41]. Analytical data were normalized to the mRNA expression level of GAPDH as an internal control. Primer sequences are described in Table 1.

**Immunoblotting**

Total cell lysates for immunoblotting were collected as previously described [43,44]. For detecting nuclear translocation of p65, nuclear extracts were prepared as previously described [43,44]. Equal amounts of protein samples were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes (Immobilon, Bedford, MA, USA). The membranes were incubated with the appropriate antibodies, washed and incubated with horseradish peroxidase-coupled secondary antibodies (Amersham, Buckinghamshire, UK). After washing, the blots were visualized by using an enhanced chemiluminescence detection system (Perkin Elmer Life Science, Boston, MA, USA).

**Small interference RNA transfections against PPARδ**

Control siRNA and siRNA against PPARδ were purchased from Ambion (Austin, TX, USA). Transient transfections of siRNA were performed using Lipofectamin 2000 (Invitrogen, Carlsbad, CA, USA) [43,44]. To determine the effect of siRNA against PPARδ on palmitate- and TNFα-induced MCP-1 expression, all experiments were performed 24 h post-siRNA transfection.

**ChIP analysis**

The ChIP experiment was performed using the ChIP-IT kit from Active Motif (Carlsbad, CA, USA) according to the manufacturer’s instructions [44]. The primer sequences are listed in Table 1.

**Retroviral infection**

pBABE-PPARδ vectors were obtained from Addgene. Retroviral infections were performed as previously described [43,44].
Briefly, HEK293T cells were transfected with pBABE and pBABE-PPARδ using Lipofectamin 2000 reagent. Forty-eight hours post-transfection, the media containing retroviruses were collected, centrifuged, and transferred into the cultured proximal tubular cells, which were pre-treated with polybrene (1 μg/mL) for 30 min. Retrovirus-infected cells were selected by treatment with puromycin (2.5 μg/mL) for several days. We confirmed over-expression of PPARδ by immunoblotting and real-time PCR.

Statistical analysis
Results are expressed as mean ± SEM. ANOVA with subsequent Scheffe test was used to determine the significance of differences in multiple comparisons. A p value <0.05 was considered statistically significant.

References
1. Abbate M, Zeza C, Remazzi G (2006) How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17: 2974–2984.
2. Burton C, Harris KP (1996) The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 27: 765–775.
3. Thomas ME, Schreiner GF (1993) Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 13: 385–398.
4. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hase H, et al. (2002) Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 62: 1628–1637.
5. Zeza C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, et al. (1998) Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 53: 1608–1615.
6. Zeza C, Garcia PB, Remuzzi G (2009) The role of chemokines in progressive renal disease. Front Biosci 14: 1815–1822.
7. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, et al. (1992) Control of the nuclear control of metabolism. Endocr Rev 20: 649–688.
8. Isemann I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645–650.
9. Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Rev 20: 649–688.
10. Duan SZ, Usher MG, Mornex RM (2009) PPARs: the vasculature, inflammation and hypertension. Curr Opin Nephrol Hypertens 18: 128–133.
11. Gervois P, Fruchart JC, Staels B (2007) Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors (PPARs). Nat Clin Pract Endocrinol Metab 3: 145–156.
12. Kamijo A, Hora K, Kono K, Takahashi K, Higuchi M, et al. (2007) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69: 1511–1517.
13. Kume S, Uza T, Ishikii K, Koya D (2008) Peroxisome proliferator-activated receptors in diabetic nephropathy. PPAR Res 2008: 879523.
14. Park CW, Zhang Y, Zhang X, Wu J, Chen L, et al. (2006) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69: 1511–1517.
15. Sarafidis PA, Bakris GL (2006) Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 70: 1223–1233.
16. 15. Park CW, Zhang Y, Zhang X, Wu J, Chen L, et al. (2006) PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69: 1511–1517.
17. Shin SJ, Lim JH, Chung S, Yoon DY, Chung HW, et al. (2009) Peroxione proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats. Hypertens Res 32: 835–845.
18. Barish GD, Atkins AR, Downes M, Olson P, Chong LW, et al. (2008) PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci U S A 105: 4271–4276.
19. Kang K, Reilly SM, Karabacak V, Gang MR, Fitzgerald K, et al. (2000) Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 7: 496–507.
20. Odegard JJ, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, et al. (2008) Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 7: 496–507.
21. Takata Y, Liu J, Yin F, Collier AR, Lyon CJ, et al. (2008) PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc Natl Acad Sci U S A 105: 4277–4282.
22. Oliver WR, Jr., Shenk JL, Smith MR, Russell CS, Plunket KD, et al. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 98: 5306–5311.
23. Kamijo Y, Hora K, Kono K, Takahashi K, Higuchi M, et al. (2007) PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol 18: 3009–3100.
24. Drumm K, Bauer B, Freundinger R, Gekle M (2002) Albumin induces NF-kappaB expression in human proximal tubule-derived cells (IHKE-1). Cell Physiol Biochem 12: 187–196.
25. Takaya K, Koya D, Isozo M, Sugimoto T, Sugaya T, et al. (2003) Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells. Am J Physiol Renal Physiol 284: F1037–1045.
26. Soumura M, Kume S, Ishikii K, Takeda N, Araki SI, et al. (2010) Oleate and eicosapentaenoic acid attenuate palmitate-induced inflammation and apoptosis in renal proximal tubular cell. Biochem Biophys Res Commun.
27. Straus DS, Glass CK (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28: 551–558.
28. Bubici C, Papa S, Dean K, Franzoso G (2006) Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 25: 6731–6748.
29. Li X, Jiang S, Tapping RI (2010) Toll-like receptor signaling in cell proliferation and survival. Cytokine 49: 1–9.

Acknowledgments
We thank Makiko Sera (Shiga University of Medical Science, Shiga, Japan) and the Central Research Laboratory of Shiga University of Medical Science for technical assistance.

Author Contributions
Conceived and designed the experiments: TU HM DL PH. Performed the experiments: XY SK YT KJ. Analyzed the data: XY SA MCK AK. Contributed reagents/materials/analysis tools: T. Sugimoto MH T. Sugaya. Wrote the paper: XY SK DK YN TU.
30. Delaney JR, Mlodzik M (2006) TGF-beta activated kinase-1: new insights into the diverse roles of TAK1 in development and immunity. Cell Cycle 5: 2852–2855.
31. Ishikado A, Nishio Y, Yamane K, Mukose A, Morino K, et al. (2009) Soy phosphatidylcholine inhibited TLR4-mediated MCP-1 expression in vascular cells. Atherosclerosis 205: 404–412.
32. Barish GD, Narkar VA, Evans RM (2006) PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590–597.
33. Lee CH, Olson P, Heyner A, Mekl I, Choug LW, et al. (2006) PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A 103: 3444–3449.
34. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, et al. (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A 100: 15924–15929.
35. Letavernier E, Perez J, Joye E, Bellocq A, Fouqueray B, et al. (2005) Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 16: 2395–2402.
36. Shimizu H, Maruyama S, Yuzawa Y, Kato T, Miki Y, et al. (2003) Anti-monocyte chemotactic protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 14: 1406–1505.
37. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, et al. (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302: 453–457.
38. Fan Y, Wang Y, Tang Z, Zhang H, Qiu X, et al. (2008) Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 28: 315–321.
39. Piqueras L, Sanz MJ, Perretti M, Morcillo E, Norling L, et al. (2009) Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol 86: 115–122.
40. Deji N, Kume S, Araki S, Soumura M, Sugimoto T, et al. (2009) Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Renal Physiol 296: F118–126.
41. Kume S, Uzu T, Araki S, Sugimoto T, Ishikai K, et al. (2007) Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 18: 2713–2723.
42. Balhmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, et al. (2004) Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 110: 1006–1012.
43. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, et al. (2007) SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 282: 151–158.
44. Kume S, Uzu T, Horiike K, Chin-Kanasaki M, Ishiki K, et al. (2010) Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 120: 1043–1055.